Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Cink
James H. Cink, St. Louis, MO US
| Patent application number | Description | Published |
|---|---|---|
| 20090094884 | TERMITE STATION WITH REPLACEABLE CARTRIDGE - A replaceable cartridge has a generally tubular sidewall constructed of a termite resistant material and an interior chamber. The sidewall has an upper end and an open lower end. An aggregation member is separate from the sidewall and positionable at least in part within the interior chamber of the sidewall generally adjacent the lower end thereof to at least in part close the lower end of the sidewall. The aggregation member is configured to define at least one opening through which termites enter the interior chamber of the sidewall through the lower end thereof. The aggregation member is constructed of a termite edible material. A bait matrix is separate from the aggregation member and disposed within the interior chamber of the sidewall intermediate the aggregation member and the upper end of the sidewall. | 04-16-2009 |
Kevin Cink, Brooklyn Park, MN US
| Patent application number | Description | Published |
|---|---|---|
| 20080262118 | Extruded Polylactide Foams Blown With Carbon Dioxide - This invention provides a process for extruding a PLA resin using high levels of CO | 10-23-2008 |
Russell D. Cink, Grayslake, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20080287676 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR - The present invention discloses novel compounds of general formula (I) | 11-20-2008 |
| 20090263477 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. | 10-22-2009 |
Russell Drew Cink, Grayslake, IL US
| Patent application number | Description | Published |
|---|---|---|
| 20090176754 | Crystalline Form of the Compound A-348441 - There is provided a hemihydrate of (3β, 5β, 7α, 12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response. | 07-09-2009 |